Anti fusobacterium nucleatum vaccine for colorectal cancer immunoprevention
Ended Awarded Last action
- Contract number
- HHSN26100004
- Awardee
-
Weill Medical College Of Cornell University UEI YNT8TCJH8FQ8 Part of Cornell University
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,246,582
Award facts
- Opportunity
-
- N01CN5500347 Solicitation number
- Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Sep 25, 2015
- Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers Award Notice · Posted Jan 5, 2015
- Contract value 100% obligated
- $1,246,582.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- New York, NY 10065, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$828 | |
| Supplemental Agreement for work within scope | -$1,585 | |
| Other Administrative Action | $0 | |
| Change Order | $49,995 | |
| Change Order | $299,000 | |
| Exercise an Option | $476,619 | |
| Original award | $423,381 |
About this award
This federal contract award, with an ID of HHSN261201500039I|HHSN26100004, was issued by the National Cancer Institute (NCI) to the Weill Medical College of Cornell University. The $1,246,582.34 Firm Fixed Price award is for the development of an anti-Fusobacterium nucleatum vaccine for colorectal cancer immunoprevention. This contract is part of the NCI's PREVENT Cancer Preclinical Drug Development Program, a multiple-award Indefinite Delivery Contract (IDC) with a $149,995,000 ceiling value. Through this larger IDC vehicle, Weill Medical College can compete for task orders to provide specialized preclinical research services, such as efficacy testing and biomarker evaluation, to advance cancer preventive agents towards clinical trials. No set-aside designation was used for this specific award. As a leading academic medical institution, the Weill Medical College of Cornell University, a subsidiary of Cornell University, has a strong track record of securing federal funding to conduct biomedical research and support the NCI's mission.
Quick answers
Who was awarded contract HHSN26100004?
HHSN26100004 was awarded to Weill Medical College Of Cornell University by National Cancer Institute (National Institutes of Health) on September 8, 2016.
How much is contract HHSN26100004 worth?
The government has obligated $1,246,582 on HHSN26100004.
Is contract HHSN26100004 an order under another contract?
Yes. HHSN26100004 is a delivery order under HHSN261201500039I, an indefinite delivery contract, on PREVENT Cancer Program (PREVENT).
Was contract HHSN26100004 competed?
The extent of competition for HHSN26100004 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award